Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb Cancer Drug Study Falls Short of Endpoints

07/16/2021 | 07:26am EDT

By Matt Grossman

Bristol Myers Squibb Co. said Friday that a trial examining Opdivo plus Yervoy as a first-line treatment in some head-and-neck-cancer patients didn't meet its primary endpoints.

The study was testing the drugs' use in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The drugs showed a positive trend toward overall survival in some patients compared with another treatment regimen, but the primary endpoints weren't achieved.

The Food and Drug Administration and the European Medicines Agency have previously approved Opdivo on its own for use in metastatic squamous cell carcinoma of the head and neck. Yervoy has also been previously approved to treat other cancers.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

07-16-21 0725ET

All news about BRISTOL-MYERS SQUIBB COMPANY
09/20BRISTOL MYERS SQUIBB : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Mela..
MT
09/20BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
BU
09/20Bristol Myers Squibb Announces FDA Accepts for Priority Review Biologics License Applic..
CI
09/20Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
DJ
09/17BRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Treating Gastr..
MT
09/17BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
BU
09/17Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo with Chemotherapy for Pa..
CI
09/17Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers
DJ
09/16Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Sinc..
DJ
09/16BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combination
MT
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 378 M - -
Net income 2021 6 495 M - -
Net Debt 2021 28 289 M - -
P/E ratio 2021 21,0x
Yield 2021 3,24%
Capitalization 135 B 135 B -
EV / Sales 2021 3,51x
EV / Sales 2022 3,16x
Nbr of Employees 30 250
Free-Float 76,0%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 60,63 $
Average target price 75,39 $
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY-2.26%133 660
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972